Unraveling the epigenetic code of cancer for therapy

Trends in Genetics

Volumn 23, Issue 9, 2007, Pages 449-456

  Smith, Laura T ^a   Otterson, Gregory A ^b   Plass, Christoph ^a  

^a Division of Human Cancer Genetics   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CHOLINE; CYANOCOBALAMIN; DEMETHYLATING AGENT; DEPSIPEPTIDE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; EPIGALLOCATECHIN GALLATE; HISTONE; HISTONE DEACETYLASE INHIBITOR; HISTONE MODIFYING AGENT; IMATINIB; INTERFERON; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERLEUKIN 2; METHIONINE; MG 98; PROCAINE; PYRIDOXINE; UNCLASSIFIED DRUG; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER GENE THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DEACETYLATION; DNA METHYLATION; DOSE RESPONSE; DRUG MECHANISM; EPIGENETICS; GENE SILENCING; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; MELANOMA; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA;

ANTINEOPLASTIC AGENTS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; GENES, NEOPLASM; GENOME; HISTONES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NUCLEIC ACID CONFORMATION;

MAMMALIA;

EID: 34547914473     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2007.07.005     Document Type: Review

References (84)

1. Wood A.J., and Oakey R.J. Genomic imprinting in mammals: emerging themes and established theories. PLoS Genet. 2 (2006) e147
2. Goto T., and Monk M. Regulation of X-chromosome inactivation in development in mice and humans. Microbiol. Mol. Biol. Rev. 62 (1998) 362-378
3. Miller O.J., et al. F. 5-Methylcytosine localised in mammalian constitutive heterochromatin. Nature 251 (1974) 636-637
4. Bird A.P. CpG-rich islands and the function of DNA methylation. Nature 321 (1986) 209-213
5. Ehrlich M., et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res. 10 (1982) 2709-2721
6. Ho S.M., and Tang W.Y. Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases. Reprod. Toxicol. 23 (2007) 267-282
7. Cowell J.K., and Hawthorn L. The application of microarray technology to the analysis of the cancer genome. Curr. Mol. Med. 7 (2007) 103-120
8. Zhang X., et al. Genome-wide high-resolution mapping and functional analysis of DNA methylation in Arabidopsis. Cell 126 (2006) 1189-1201
9. Zilberman D., et al. Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an interdependence between methylation and transcription. Nat. Genet. 39 (2007) 61-69
10. Sandovici I., et al. Interindividual variability and parent of origin DNA methylation differences at specific human Alu elements. Hum. Mol. Genet. 14 (2005) 2135-2143
11. Petronis A. Epigenetics and twins: three variations on the theme. Trends Genet. 22 (2006) 347-350
12. Rakyan V.K., et al. DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. PLoS Biol. 2 (2004) e405
13. Eckhardt F., et al. DNA methylation profiling of human chromosomes 6. Nat. Genet. 38 (2006) 1378-1385
14. Hattori N., et al. Epigenetic regulation of NANOG gene in embryonic stem and trophoblast stem cells. Genes Cells 12 (2007) 387-396
15. Song F., et al. Association of tissue-specific differentially methylated regions (TDMs) with differential gene expression. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3336-3341
16. Gaudet F., et al. Induction of tumors in mice by genomic hypomethylation. Science 300 (2003) 489-492
17. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 21 (2002) 5400-5413
18. Rougier N. Chromosome methylation patterns during mammalian preimplantation development. Genes Dev. 12 (1998) 2108-2113
19. Barreto G., et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 445 (2007) 671-675
20. Santos-Reboucas C.B., and Pimentel M.M. Implication of abnormal epigenetic patterns for human diseases. Eur. J. Hum. Genet. 15 (2006) 10-17
21. Rodenhiser D., and Mann M. Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 174 (2006) 341-348
22. Trasler J., et al. Impact of Dnmt1 deficiency, with and without low folate diets, on tumor numbers and DNA methylation in Min mice. Carcinogenesis 24 (2003) 39-45
23. Smiraglia D., et al. Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors. Oncogene 21 (2002) 3909-3916
24. Costello J.F., et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24 (2000) 132-138
25. Esteller M., et al. A gene hypermethylation profile of human cancer. Cancer Res. 61 (2001) 3225-3229
26. Robertson K.D., et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 27 (1999) 2291-2298
27. Robertson K.D., et al. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Res. 28 (2000) 2108-2113
28. Di Croce L., et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295 (2002) 1079-1082
29. Brenner C., et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J. 24 (2005) 336-346
30. Tabe Y., et al. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Ann. Hematol. 85 (2006) 689-704
31. Feltus F.A., et al. Predicting aberrant CpG island methylation. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12253-12258
32. Feldman N., et al. G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat. Cell Biol. 8 (2006) 188-194
33. Tagoh H., et al. The mechanism of repression of the myeloid-specific c-fms gene by Pax5 during B lineage restriction. EMBO J. 25 (2006) 1070-1080
34. Stirzaker C., et al. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res. 64 (2004) 3871-3877
35. Berger S.L. The complex language of chromatin regulation during transcription. Nature 447 (2007) 407-412
36. Cheung P., and Lau P. Epigenetic regulation by histone methylation and histone variants. Mol. Endocrinol. 19 (2005) 563-573
37. Gilbert J., et al. The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin. Cancer Res. 10 (2004) 4589-4596
38. Dolinoy D.C., et al. Epigenetic gene regulation: linking early developmental environment to adult disease. Reprod. Toxicol. 23 (2006) 297-307
39. Jenuwein T. The epigenetic magic of histone lysine methylation. FEBS J. 273 (2006) 3121-3135
40. Peters A.H., et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107 (2001) 323-337
41. Bannister A.J., et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410 (2001) 120-124
42. Fraga M.F., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37 (2005) 391-400
43. Taverna S.D., et al. Long-distance combinatorial linkage between methylation and acetylation on histone H3 N termini. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 2086-2091
44. Sims J.K., et al. A trans-tail histone code defined by monomethylated H4 Lys-20 and H3 Lys-9 demarcates distinct regions of silent chromatin. J. Biol. Chem. 281 (2006) 12760-12766
45. Fuks F., et al. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24 (2000) 88-91
46. Leu Y.W., et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res. 64 (2004) 8184-8192
47. Jackson J.P., et al. Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase. Nature 416 (2002) 556-560
48. Tamaru H., and Selker E.U. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 414 (2001) 277-283
49. Cameron E.E., et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21 (1999) 103-107
50. Zhao Z., and Jiang C. Methylation-dependent transition rates are dependent on local sequence lengths and genomic regions. Mol. Biol. Evol. 24 (2006) 23-25
51. Cai S., et al. SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat. Genet. 38 (2006) 1278-1288
52. Zhang Y., et al. DNA translocation and loop formation mechanism of chromatin remodeling by SWI/SNF and RSC. Mol. Cell 24 (2006) 559-568
53. Gius D., et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6 (2004) 361-371
54. Lubbert M., et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br. J. Haematol. 114 (2001) 349-357
55. Silverman L.R., and Mufti G.J. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat. Clin. Pract. Oncol. 2 Suppl 1 (2005) S12-S23
56. Momparler R.L., et al. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8 (1997) 358-368
57. Thibault A., et al. A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84 (1998) 87-89
58. Schrump D.S., et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res. 12 (2006) 5777-5785
59. Juttermann R., et al. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 11797-11801
60. Davis A.J., et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest. New Drugs 21 (2003) 85-97
61. Stresemann C., et al. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 66 (2006) 2794-2800
62. Marks P.A., et al. Histone deacetylases. Curr. Opin. Pharmacol. 3 (2003) 344-351
63. Hellebrekers D.M., et al. Dual targeting of epigenetic therapy in cancer. Biochim. Biophys. Acta. 1775 (2006) 76-91
64. Kim M.S., et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7 (2001) 437-443
65. Deroanne C.F., et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21 (2002) 427-436
66. Heider U., et al. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur. J. Haematol. 76 (2006) 42-50
67. Miki K., et al. Demethylation by 5-aza-2′-deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer cell lines. Oncol. Res. 12 (2001) 335-342
68. Qian D.Z., et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 12 (2006) 634-642
69. Yeow W.S., et al. Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. Br. J. Cancer 94 (2006) 1436-1445
70. Chavez-Blanco A., et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol. Cancer 4 (2005) 22
71. Gilbert J., et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 7 (2001) 2292-2300
72. Aron J.L., et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102 (2003) 652-658
73. Sandor V., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8 (2002) 718-728
74. Coomber B.L., et al. Angiogenesis and the role of epigenetics in metastasis. Clin. Exp. Metastasis 20 (2003) 215-227
75. Perez-Plasencia C., and Duenas-Gonzalez A. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?. Mol. Cancer 5 (2006) 27
76. Hamilton J.P., et al. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin. Gastroenterol. Hepatol. 4 (2006) 701-708
77. Glasspool R., et al. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer 94 (2006) 1087-1092
78. Reu F.J., et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J. Clin. Oncol. 24 (2006) 3771-3779
79. Fulda S., and Debatin K.M. 5-Aza-2′-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 25 (2006) 5125-5133
80. Berman B., et al. Immunological strategies to fight skin cancer. Skin Therapy Lett. 11 (2006) 1-7
81. Yang D., et al. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res. 67 (2007) 3301-3309
82. Gollob J.A., et al. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin. Cancer Res. 12 (2006) 4619-4627
83. Issa J.P., et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J. Clin. Oncol. 23 (2005) 3948-3956
84. Munshi A., et al. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol. Cancer Ther. 5 (2006) 1967-1974